Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 9/2020

01-09-2020 | Respiratory Microbiota | Nutrition (P. Kris-Etherton and K. Petersen, Section Editor)

Nutrition and Gastrointestinal Microbiota, Microbial-Derived Secondary Bile Acids, and Cardiovascular Disease

Authors: Jose Rodríguez-Morató, Nirupa R. Matthan

Published in: Current Atherosclerosis Reports | Issue 9/2020

Login to get access

Abstract

Purpose of Review

The goal is to review the connection between gut microbiota and cardiovascular disease, with specific emphasis on bile acids, and the influence of diet in modulating this relationship.

Recent Findings

Bile acids exert a much broader range of biological functions than initially recognized, including regulation of cardiovascular function through direct and indirect mechanisms. There is a bi-directional relationship between gut microbiota modulation of bile acid–signaling properties, and their effects on gut microbiota composition. Evidence, primarily from rodent models and limited human trials, suggest that dietary modulation of the gut microbiome significantly impacts bile acid metabolism and subsequently host physiological response(s).

Summary

Available evidence suggests that the link between diet, gut microbiota, and CVD risk is potentially mediated via bile acid effects on diverse metabolic pathways. However, further studies are needed to confirm/expand and translate these findings in a clinical setting.
Literature
1.
2.
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63.PubMedCrossRef
3.
Sheflin AM, Melby CL, Carbonero F, Weir TL. Linking dietary patterns with gut microbial composition and function. Gut Microbes. 2017;8(2):113–29.PubMedCrossRef
4.
Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14(2):79–87.PubMedCrossRef
5.
• Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell 2018: 9(5):416–431. Detailed overview of various gut-derived metabolites and their role in CVD.
6.
Martinez KB, Leone V, Chang EB. Microbial metabolites in health and disease: navigating the unknown in search of function. J Biol Chem. 2017;292(21):8553–9.PubMedPubMedCentralCrossRef
7.
• Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal microbiota in cardiovascular health and disease (JACC State-of-the-Art Review). J Am Coll Cardiol. 2019: 73(16);2089–2105. Recent review focused on human intestinal microbiota and its potential modulation to improve cardiovascular health.
8.
Fu BC, Hullar MAJ, Randolph TW, et al. Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. Am J Clin Nutr. 2020:13(10).
9.
Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50.PubMedCrossRef
10.
11.
Feng Q, Liu Z, Zhong S, et al. Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease. Sci Rep. 2016:6(22525).
12.
Lin CJ, Chuang CK, Jayakumar T, Liu HL, Pan CF, Wang TJ, et al. Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients. Arch Med Sci. 2013;9(4):662–8.PubMedPubMedCentralCrossRef
13.
Poesen R, Claes K, Evenepoel P, de Loor H, Augustijns P, Kuypers D, et al. Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD. J Am Soc Nephrol. 2016;27(11):3479–87.PubMedPubMedCentralCrossRef
14.
Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Int Med. 1999;159(22):2647–58.CrossRef
15.
Šarenac TM, Mikov M. Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients. Front Pharmacol. 2018;9(939).
16.
Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Molec Med. 2015;21(11):702–14.CrossRef
17.
Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009;108(2):225–46.PubMedCrossRef
18.
Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65(16):2461–83.PubMedCrossRef
19.
Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile acid physiology. Ann Hepatol 2017: 16(Suppl. 1: s3–105.):s4-s14.
20.
Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137–74.PubMedCrossRef
21.
Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731–44.PubMedCrossRef
22.
Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med. 2007;7(2):199–218.PubMedCrossRef
23.
Hundt M, Basit H. John S. Bile Secretion: Physiology; 2020.
24.
• Molinero N, Ruiz L, Sánchez B, Margolles A, Delgado S. Intestinal bacteria interplay with bile and cholesterol metabolism: implications on host physiology. Front Physiol 2019: 10:185–185. A detailed overview of bile acid physiology and its reciprocal relationship with gut microbiota.
25.
Chiang JYL. Bile acids: regulation of synthesis. J Lip Res. 2009;50(10):1955–66.CrossRef
26.
Busnelli M, Manzini S, Chiesa G. The gut microbiota affects host pathophysiology as an endocrine organ: a focus on cardiovascular disease. Nutrients 2019: 12(1).
27.
Chen ML, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunol. 2019;12(4):851–61.PubMedCrossRef
28.
Sarafian MH, Lewis MR, Pechlivanis A, Ralphs S, McPhail MJW, Patel VC, et al. Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem. 2015;87(19):9662–70.PubMedCrossRef
29.
Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis. 2015;33(3):327–31.PubMedCrossRef
30.
Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease. Mediat Inflamm. 2019;2019:7659509.
31.
Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014;11(1):55–67.PubMedCrossRef
32.
Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362–5.PubMedCrossRef
33.
Song P, Rockwell CE, Cui JY, Klaassen CD. Individual bile acids have differential effects on bile acid signaling in mice. Toxicol Appl Pharmacol. 2015;283(1):57–64.PubMedCrossRefPubMedCentral
34.
Khurana S, Raufman J-P, Pallone TL. Bile acids regulate cardiovascular function. Clin Trans Sci. 2011;4(3):210–8.CrossRef
35.
Sannasiddappa TH, Lund PA, Clarke SR. In vitro antibacterial activity of unconjugated and conjugated bile salts on Staphylococcus aureus. Front Microbiol. 2017;8:1581.PubMedPubMedCentralCrossRef
36.
Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111–28.PubMedCrossRef
37.
Trottier J, Caron P, Straka RJ, Barbier O. Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. Clin Pharmacol Ther. 2011;90(2):279–86.PubMedCrossRef
38.
Charach G, Karniel E, Novikov I, Galin L, Vons S, Grosskopf I, et al. Reduced bile acid excretion is an independent risk factor for stroke and mortality: a prospective follow-up study. Atherosclerosis. 2020;293:79–85.PubMedCrossRef
39.
Li Y, Zhang D, He Y, et al. Investigation of novel metabolites potentially involved in the pathogenesis of coronary heart disease using a UHPLC-QTOF/MS-based metabolomics approach. Sci Rep. 2017;7(1):017–15737.CrossRef
40.
Charach G, Grosskopf I, Rabinovich A, Shochat M, Weintraub M, Rabinovich P. The association of bile acid excretion and atherosclerotic coronary artery disease. Ther Adv Gastroenterol. 2011;4(2):95–101.CrossRef
41.
Rajaratnam RA, Gylling H, Miettinen TA. Cholesterol absorption, synthesis, and fecal output in postmenopausal women with and without coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21(10):1650–5.PubMedCrossRef
42.
Li W, Shu S, Cheng L, Hao X, Wang L, Wu Y, et al. Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction and severity of coronary lesions. Atherosclerosis. 2020;292:193–200.PubMedCrossRef
43.
Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity. 2009;17(9):1671–7.PubMedCrossRef
44.
Sun W, Zhang D, Wang Z, et al. Insulin resistance is associated with total bile acid level in type 2 diabetic and nondiabetic population: a cross-sectional study. Medicine. 2016;95(10):002778.
45.
Battson ML, Lee DM, Weir TL, Gentile CL. The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem. 2018;56:1–15.PubMedCrossRef
46.
Vasavan T, Ferraro E, Ibrahim E, Dixon P, Gorelik J, Williamson C. Heart and bile acids - clinical consequences of altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis 2018: 1864(4 Pt B):1345–1355.
47.
Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, et al. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2006;26(10):2316–21.PubMedCrossRef
48.
Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14(6):747–57.PubMedPubMedCentralCrossRef
49.
Jadhav K, Xu Y, Li Y, et al. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol Metab. 2018;9:131–40.PubMedPubMedCentralCrossRef
50.
Miyazaki-Anzai S, Masuda M, Kohno S, Levi M, Shiozaki Y, Keenan AL, et al. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. J Lip Res. 2018;59(9):1709–13.CrossRef
51.
52.
Kundu S, Bansal S, Muthukumarasamy KM, Sachidanandan C, Motiani RK, Bajaj A. Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using in vitro and in vivo model systems. Medchemcomm. 2017;8(12):2248–57.PubMedPubMedCentralCrossRef
53.
Takahashi S, Luo Y, Ranjit S, et al. Bile acid sequestration reverses liver injury and prevents progression of NASH in Western diet-fed mice. J Biol Chem 2020:jbc.RA119.011913.
54.
Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl. 1994;204:1–15.PubMedCrossRef
55.
Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N. Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver Disease. Pharmaceuticals. 2018;11(4):104.PubMedCentralCrossRef
56.
Ðanić M, Stanimirov B, Pavlović N, et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol. 2018:9(1382).
57.
Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15(1):017–1175.CrossRef
58.
Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7(4):2839–49.PubMedPubMedCentralCrossRef
59.
Yokota A, Fukiya S, Islam KB, et al. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut Microbes. 2012;3(5):455–9.PubMedCrossRef
60.
Bisschop PH, Bandsma RH, Stellaard F, et al. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am J Clin Nutr. 2004;79(4):570–6.PubMedCrossRef
61.
Brassard D, Tessier-Grenier M, Allaire J, Rajendiran E, She Y, Ramprasath V, et al. Comparison of the impact of SFAs from cheese and butter on cardiometabolic risk factors: a randomized controlled trial. Am J Clin Nutr. 2017;105(4):800–9.PubMedCrossRef
62.
Mokkala K, Houttu N, Cansev T, Laitinen K. Interactions of dietary fat with the gut microbiota: evaluation of mechanisms and metabolic consequences. Clin Nutr. 2020;39(4):994–1018.PubMedCrossRef
63.
Devkota S, Chang EB. Interactions between diet, bile acid metabolism, gut microbiota, and inflammatory bowel diseases. Dig Dis. 2015;33(3):351–6.PubMedCrossRef
64.
Meng H, Matthan NR, Wu D, Li L, Rodríguez-Morató J, Cohen R, et al. Comparison of diets enriched in stearic, oleic, and palmitic acids on inflammation, immune response, cardiometabolic risk factors, and fecal bile acid concentrations in mildly hypercholesterolemic postmenopausal women-randomized crossover trial. Am J Clin Nutr. 2019;110(2):305–15.PubMedCrossRef
65.
Madsen L, Myrmel LS, Fjære E, Liaset B, Kristiansen K. Links between dietary protein sources, the gut microbiota, and obesity. Front Physiol 2017: 8(1047).
66.
Alemán JO, Bokulich NA, Swann JR, et al. Fecal microbiota and bile acid interactions with systemic and adipose tissue metabolism in diet-induced weight loss of obese postmenopausal women. J Transl Med. 2018;16(1):018–1619.CrossRef
67.
Arellano-Martínez GL, Granados O, Palacios-González B, Torres N, Medina-Vera I, Tovar AR. Soya protein stimulates bile acid excretion by the liver and intestine through direct and indirect pathways influenced by the presence of dietary cholesterol. Br J Nutr. 2014;111(12):2059–66.PubMedCrossRef
68.
Bortolotti M, Kreis R, Debard C, Cariou B, Faeh D, Chetiveaux M, et al. High protein intake reduces intrahepatocellular lipid deposition in humans. Am J Clin Nutr. 2009;90(4):1002–10.PubMedCrossRef
69.
Tomova A, Bukovsky I, Rembert E, et al. The effects of vegetarian and vegan diets on gut microbiota. Front Nutr. 2019:6(47).
70.
Trefflich I, Marschall HU, Giuseppe RD, et al. Associations between dietary patterns and bile acids-results from a cross-sectional study in vegans and omnivores. Nutrients. 2019:12(1).
71.
Watanabe K, Igarashi M, Li X, et al. Dietary soybean protein ameliorates high-fat diet-induced obesity by modifying the gut microbiota-dependent biotransformation of bile acids. PLoS One. 2018:13(8).
72.
Spielmann J, Stangl GI, Eder K. Dietary pea protein stimulates bile acid excretion and lowers hepatic cholesterol concentration in rats. J Anim Physiol Anim Nutr. 2008;92(6):683–93.CrossRef
73.
Weickert MO, Hattersley JG, Kyrou I, et al. Effects of supplemented isoenergetic diets varying in cereal fiber and protein content on the bile acid metabolic signature and relation to insulin resistance. Nutr Diabetes. 2018;8(1):018–0020.CrossRef
74.
Hills RD, Jr., Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut microbiome: profound implications for diet and disease. Nutrients 2019: 11(7).
75.
Soliman GA. Dietary Fiber, Atherosclerosis, and Cardiovascular Disease. Nutrients 2019: 11(5).
76.
Gunness P, Michiels J, Vanhaecke L, Smet S, Kravchuk O, van de Meene A, et al. Reduction in circulating bile acid and restricted diffusion across the intestinal epithelium are associated with a decrease in blood cholesterol in the presence of oat β-glucan. FASEB J. 2016;30(12):4227–38.PubMedCrossRef
77.
Ginos BNR, Navarro SL, Schwarz Y, Gu H, Wang D, Randolph TW, et al. Circulating bile acids in healthy adults respond differently to a dietary pattern characterized by whole grains, legumes and fruits and vegetables compared to a diet high in refined grains and added sugars: a randomized, controlled, crossover feeding study. Metabolism. 2018;83:197–204.PubMedPubMedCentralCrossRef
78.
Connolly ML, Tzounis X, Tuohy KM, Lovegrove JA. Hypocholesterolemic and prebiotic effects of a whole-grain oat-based granola breakfast cereal in a cardio-metabolic “at risk” population. Front Microbiol 2016: 7(1675).
79.
Hollænder PL, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr. 2015;102(3):556–72.PubMedCrossRef
80.
Morton GJ, Kaiyala KJ, Foster-Schubert KE, Cummings DE, Schwartz MW. Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans. J Clin Endocrinol Metab. 2014;99(2):2013–3129.CrossRef
81.
Apro J, Beckman L, Angelin B, Rudling M. Influence of dietary sugar on cholesterol and bile acid metabolism in the rat: marked reduction of hepatic Abcg5/8 expression following sucrose ingestion. Biochem Biophys Res Comm. 2015;461(4):592–7.PubMedCrossRef
82.
Chambers KF, Day PE, Aboufarrag HT, Kroon PA. Polyphenol effects on cholesterol metabolism via bile acid biosynthesis, CYP7A1: a review. Nutrients 2019: 11(11).
83.
Rodríguez-Morató J, Matthan NR, Liu J, de la Torre R, Chen CO. Cranberries attenuate animal-based diet-induced changes in microbiota composition and functionality: a randomized crossover controlled feeding trial. J Nutr Biochem. 2018;62:76–86.PubMedCrossRef
84.
Holscher HD, Guetterman HM, Swanson KS, An R, Matthan NR, Lichtenstein AH, et al. Walnut consumption alters the gastrointestinal microbiota, microbially derived secondary Bile acids, and health markers in healthy adults: a randomized controlled trial. J Nutr. 2018;148(6):861–7.PubMedPubMedCentralCrossRef
85.
Tindall AM, McLimans CJ, Petersen KS, Kris-Etherton PM, Lamendella R. Walnuts and vegetable oils containing oleic acid differentially affect the gut microbiota and associations with cardiovascular risk factors: follow-up of a randomized, controlled, feeding trial in adults at risk for cardiovascular disease. J Nutr. 2020;150(4):806–17.PubMedCrossRef
86.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.PubMedPubMedCentralCrossRef
87.
Koeth RA, Lam-Galvez BR, Kirsop J, Wang Z, Levison BS, Gu X, et al. L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. 2019;129(1):373–87.PubMedCrossRef
88.
Ding L, Chang M, Guo Y, et al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. Lipids Health Dis. 2018;17(1):018–0939.CrossRef
89.
Pavlović N, Stankov K, Mikov M. Probiotics--interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol. 2012;168(7):1880–95.PubMedCrossRef
90.
Jones ML, Tomaro-Duchesneau C, Prakash S. The gut microbiome, probiotics, bile acids axis, and human health. Trends Microbiol. 2014;22(6):306–8.PubMedCrossRef
91.
Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. PNAS. 2014;111(20):7421–6.PubMedCrossRefPubMedCentral
92.
Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014;7(1):12–8.PubMedCrossRef
93.
• Tindall AM, Petersen KS, Kris-Etherton PM. Dietary patterns affect the gut microbiome-the link to risk of cardiometabolic diseases. J Nutr 2018: 148(9):1402–1407. Brief review of the relationship between specific dietary patterns and cardiovascular disease.
94.
95.
Sheng L, Jena PK, Liu HX, et al. Gender differences in Bile acids and microbiota in relationship with gender dissimilarity in steatosis induced by diet and FXR inactivation. Sci Rep. 2017;7(1):017–01576.CrossRef
96.
Baars A, Oosting A, Lohuis M, et al. Sex differences in lipid metabolism are affected by presence of the gut microbiota. Sci Rep. 2018;8(1):018–31695.CrossRef
97.
Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One. 2011;6(10):e25482.PubMedPubMedCentralCrossRef
98.
Miyata M, Takamatsu Y, Kuribayashi H, Yamazoe Y. Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast growth factor 15 expression. J Pharmacol Exp Ther. 2009;331(3):1079–85.PubMedCrossRef
99.
Wang W, Cheng Z, Wang Y, Dai Y, Zhang X, Hu S. Role of bile acids in bariatric surgery. Front Physiol 2019: 10(374).
100.
Steiner C, Othman A, Saely CH, et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One. 2011;6(11):14.CrossRef
101.
Yin S, Su M, Xie G, Li X, Wei R, Liu C, et al. Factors affecting separation and detection of bile acids by liquid chromatography coupled with mass spectrometry in negative mode. Anal Bioanal Chem. 2017;409(23):5533–45.PubMedPubMedCentralCrossRef
102.
Thakare R, Alamoudi JA, Gautam N, Rodrigues AD, Alnouti Y. Species differences in bile acids I. Plasma and urine bile acid composition. J Appl Toxicol. 2018;38(10):1323–35.PubMedCrossRef
103.
Rodríguez-Morató J, Pozo ÓJ, Marcos J. Targeting human urinary metabolome by LC-MS/MS: a review. Bioanalysis. 2018;10(7):489–516.PubMedCrossRef
104.
Steiner C, von Eckardstein A, Rentsch KM. Quantification of the 15 major human bile acids and their precursor 7α-hydroxy-4-cholesten-3-one in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2010;878(28):2870–80.CrossRef
105.
Reinicke M, Schröter J, Müller-Klieser D, Helmschrodt C, Ceglarek U. Free oxysterols and bile acids including conjugates - simultaneous quantification in human plasma and cerebrospinal fluid by liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2018;11:245–55.CrossRef
106.
• Dutta M, Cai J, Gui W, Patterson AD. A review of analytical platforms for accurate bile acid measurement. Anal Bioanal Chem 2019: 411(19):4541–4549. Recent summary of different detection technologies commonly employed for the measurement of bile acids.
107.
Hosomi R, Matsudo A, Sugimoto K, Shimono T, Kanda S, Nishiyama T, et al. Dietary fat influences the expression of genes related to sterol metabolism and the composition of cecal microbiota and its metabolites in rats. J Oleo Sci. 2019;68(11):1133–47.PubMedCrossRef
Metadata
Title
Nutrition and Gastrointestinal Microbiota, Microbial-Derived Secondary Bile Acids, and Cardiovascular Disease
Authors
Jose Rodríguez-Morató
Nirupa R. Matthan
Publication date
01-09-2020
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 9/2020
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-020-00863-7

Other articles of this Issue 9/2020

Current Atherosclerosis Reports 9/2020 Go to the issue

Evidence-Based Medicine, Clinical Trials and Their Interpretations (L. Roever,Section Editor)

Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis

Women and Ischemic Heart Disease (P. Kohli, Section Editor)

Spontaneous Coronary Artery Dissection: Latest Developments and New Frontiers

Women and Ischemic Heart Disease (P. Kohli, Section Editor)

The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women

Statin Drugs (R. Ceska, Section Editor)

The Role of Statins in Current Guidelines

Hot Topics in Atherosclerosis (A Gotto, Section Editor)

Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis

Coronary Heart Disease (S. Virani and S. Naderi, Section Editor)

Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits